Curis, Inc.
Curis develops emavusertib, an oral small molecule IRAK4 and FLT3 inhibitor in Phase 1/2 and Phase 2 studies for relapsed/refractory primary central nervous system lymphoma and chronic lymphocytic leukemia in combination with BTK inhibitors, and monotherapy studies in acute myeloid leukemia and myelodysplastic syndrome.
SCHEDULE 13GNov 16Latest SEC filing
Nov 13Latest story